Source: https://www.itnonline.com/content/forbes-ai-50-selects-nines-one-most-promising-ai-companiesAfter radiosurgery concurrent with nivolumab in 59-year-old patient with melanoma BM (patient 1; Supplemental Tables 3 and 5), F-18 FET PET at follow-up 12 weeks after treatment initiation (bottom row) shows significant decrease of metabolic activity (TBRmean, ?28%) compared with baseline (top row), although MRI changes were consistent with progression according to iRANO criteria. Reduction of metabolic activity was associated with stable clinical course over 10 mo. CE = contrast-enhanced. Image created by N. Galldiks et al., Research Center Juelich, Juelich, Germany.
Forbes AI 50 Selects Nines as one of the Most Promising AI Companies
AITime Stamp: May 6, 2021 10:29 AM
Source Node: 845684